| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1003285366 |
| P356 | DOI | 10.1186/1748-717X-7-60 |
| P8608 | Fatcat ID | release_cs655lhtbbfpvf2bg3pndfq4aa |
| P932 | PMC publication ID | 3364842 |
| P698 | PubMed publication ID | 22501022 |
| P50 | author | Claus Belka | Q89799331 |
| P2093 | author name string | Michael Schmidt | |
| Franz Zehentmayr | |||
| Dieter Hölzel | |||
| Maria C Wolf | |||
| P2860 | cites work | Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus | Q24244706 |
| Cancer statistics, 2008 | Q27860585 | ||
| Excess incidence of squamous cell esophageal cancer among US Black men: role of social class and other risk factors | Q31834535 | ||
| Late treatment with imatinib mesylate ameliorates radiation-induced lung fibrosis in a mouse model | Q33574341 | ||
| Radiosensitization and growth inhibition of cancer cells mediated by an scFv antibody gene against DNA-PKcs in vitro and in vivo | Q33655527 | ||
| Prescreening based on the presence of CT-scan abnormalities and biomarkers (KL-6 and SP-D) may reduce severe radiation pneumonitis after stereotactic radiotherapy | Q33875793 | ||
| Analysis of clinical and dosimetric factors associated with severe acute radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent chemotherapy and intensity-modulated radiotherapy | Q33907268 | ||
| Four-dimensional dosimetry validation and study in lung radiotherapy using deformable image registration and Monte Carlo techniques | Q33933920 | ||
| Trends in survival for both histologic types of esophageal cancer in US surveillance, epidemiology and end results areas | Q34187865 | ||
| Large volume unresectable locally advanced non-small cell lung cancer: acute toxicity and initial outcome results with rapid arc | Q34273793 | ||
| The value of metabolic imaging to predict tumour response after chemoradiation in locally advanced rectal cancer | Q34448045 | ||
| Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction | Q34603020 | ||
| Multiple management modalities in esophageal cancer: combined modality management approaches | Q35718915 | ||
| Treatment of localized esophageal cancer | Q35857449 | ||
| Adenocarcinoma of the esophagus and cardia: a review of the disease and its treatment | Q36353709 | ||
| Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer: evidence of a radiation and chemotherapy dose response | Q36424588 | ||
| New classification of oesophageal and gastric carcinomas derived from changing patterns in epidemiology | Q36617794 | ||
| Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities | Q36836275 | ||
| AT-101, a small molecule inhibitor of anti-apoptotic Bcl-2 family members, activates the SAPK/JNK pathway and enhances radiation-induced apoptosis | Q37406947 | ||
| Evidence-based radiation oncology: oesophagus | Q37449371 | ||
| Lack of Cetuximab induced skin toxicity in a previously irradiated field: case report and review of the literature | Q37755493 | ||
| Curative treatment of oesophageal carcinoma: current options and future developments | Q37880292 | ||
| Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. | Q39737918 | ||
| Staging investigations for oesophageal cancer: a meta-analysis | Q41972285 | ||
| Long-term outcome of mitomycin C- and 5-FU-based primary radiochemotherapy for esophageal cancer | Q43003938 | ||
| High incidence of synchronous cancer of the oral cavity and the upper gastrointestinal tract | Q43757861 | ||
| Changing patterns in the incidence of esophageal and gastric carcinoma in the United States | Q43873434 | ||
| Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. | Q44022873 | ||
| Trends in the management of esophageal carcinoma based on provider volume: treatment practices of 618 esophageal surgeons | Q45402608 | ||
| Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus | Q46412803 | ||
| Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. | Q46675470 | ||
| Multicenter prospective randomized trial comparing standard esophagectomy with chemoradiotherapy for treatment of squamous esophageal cancer: early results from the Chinese University Research Group for Esophageal Cancer (CURE). | Q46723357 | ||
| Recommendations on the use of 18F-FDG PET in oncology | Q46744015 | ||
| Survival effect of neoadjuvant radiotherapy before esophagectomy for patients with esophageal cancer: a surveillance, epidemiology, and end-results study. | Q51699297 | ||
| Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. | Q53491085 | ||
| An analysis of multiple staging management strategies for carcinoma of the esophagus: computed tomography, endoscopic ultrasound, positron emission tomography, and thoracoscopy/laparoscopy. | Q53667969 | ||
| Esophageal Cancer | Q56209683 | ||
| Long-term results of infusional 5-FU, mitomycin-C, and radiation as primary management of esophageal carcinoma | Q67681208 | ||
| Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus | Q68122887 | ||
| A comparison of multimodal therapy and surgery for esophageal adenocarcinoma | Q71164736 | ||
| Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study | Q71975350 | ||
| Chemoradiotherapy Followed by Surgery Compared with Surgery Alone in Squamous-Cell Cancer of the Esophagus | Q73502951 | ||
| Guidelines for the management of oesophageal and gastric cancer | Q74241859 | ||
| Demographic variations in the rising incidence of esophageal adenocarcinoma in white males | Q74373937 | ||
| Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group | Q77424043 | ||
| INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy | Q77706014 | ||
| Patterns of care and effects on mortality for cancers of the oesophagus and gastric cardia: a population-based study | Q79399284 | ||
| Treatment-outcome for synchronous head-and-neck and oesophageal squamous cell carcinoma | Q81194708 | ||
| The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence | Q81290009 | ||
| Treatment of esophageal cancer based on histology: a surveillance epidemiology and end results analysis | Q83769323 | ||
| P275 | copyright license | Creative Commons Attribution 2.0 Generic | Q19125117 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P304 | page(s) | 60 | |
| P577 | publication date | 2012-04-15 | |
| P1433 | published in | Radiation Oncology | Q2313370 |
| P1476 | title | Treatment strategies for oesophageal cancer - time-trends and long term outcome data from a large tertiary referral centre | |
| P478 | volume | 7 |
| Q49847272 | Importance of Pancreatic Enzyme Replacement Therapy after Surgery of Cancer of the Esophagus or the Esophagogastric Junction |
| Q39233604 | Mechanistic target of rapamycin small interfering RNA and rapamycin synergistically inhibit tumour growth in a mouse xenograft model of human oesophageal carcinoma |
| Q35835137 | Prognostic factors, patterns of recurrence and toxicity for patients with esophageal cancer undergoing definitive radiotherapy or chemo-radiotherapy |
| Q49166159 | Radiotherapy for esophageal carcinoma: dose, response and survival |
| Q38859349 | Which interval is most crucial to presentation and survival in gastroesophageal cancer: A systematic review. |
Search more.